United Therapeutics Corp. (UTHR) Lifted to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of United Therapeutics Corp. (NASDAQ:UTHR) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning. The firm currently has $137.00 price target on the biotechnology company’s stock.
According to Zacks, “United Therapeutics holds a strong position in the pulmonary arterial hypertension (PAH) market with four approved products targeting this indication. The company’s latest PAH offering, Orenitram, should continue to witness a pick-up in sales on the back of new patient starts, increasing patient referrals, and increasing uptake in community centers. However, PAH sales could be impacted by the warehousing effect with patients waiting to be treated with newer products like Orenitram and Actelion’s Uptravi. Meanwhile, we believe the company needs to use cash suitably to deal with generic competition for flagship product Remodulin that could materialize post Oct 2017 and should work on expanding its portfolio. Tyvaso and Orenitram are also facing patent challenges. Competition in the PAH market is also increasing.”
UTHR has been the subject of several other reports. Cowen and Company reissued a buy rating and set a $144.00 price target on shares of United Therapeutics Corp. in a report on Friday, September 23rd. JPMorgan Chase & Co. dropped their price target on United Therapeutics Corp. from $145.00 to $129.00 and set a neutral rating for the company in a report on Friday, July 29th. HC Wainwright cut United Therapeutics Corp. from a buy rating to a neutral rating and dropped their price target for the stock from $175.00 to $95.00 in a report on Wednesday, June 15th. Jefferies Group reissued a hold rating and set a $120.00 price target on shares of United Therapeutics Corp. in a report on Friday, July 29th. Finally, Argus reissued a hold rating on shares of United Therapeutics Corp. in a report on Tuesday, August 23rd. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $137.09.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) opened at 118.08 on Wednesday. United Therapeutics Corp. has a one year low of $97.52 and a one year high of $164.04. The company has a market cap of $5.13 billion, a PE ratio of 5.71 and a beta of 1.42. The stock’s 50 day moving average price is $123.53 and its 200 day moving average price is $115.94.
United Therapeutics Corp. (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 28th. The biotechnology company reported $4.55 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.22 by $1.33. The business earned $412.60 million during the quarter, compared to analysts’ expectations of $395.15 million. United Therapeutics Corp. had a return on equity of 49.30% and a net margin of 64.26%. The firm’s revenue for the quarter was up 18.8% compared to the same quarter last year. During the same period last year, the firm posted $2.55 EPS. Equities analysts predict that United Therapeutics Corp. will post $15.82 earnings per share for the current fiscal year.
In related news, CEO Martine A. Rothblatt sold 1,249 shares of the business’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $125.78, for a total transaction of $157,099.22. Following the sale, the chief executive officer now owns 1,389 shares in the company, valued at approximately $174,708.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher Patusky sold 5,000 shares of the business’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $122.73, for a total value of $613,650.00. Following the sale, the director now owns 5,000 shares in the company, valued at approximately $613,650. The disclosure for this sale can be found here. Corporate insiders own 7.50% of the company’s stock.
A number of large investors have recently modified their holdings of UTHR. Scopia Capital Management LP raised its stake in shares of United Therapeutics Corp. by 48.1% in the first quarter. Scopia Capital Management LP now owns 4,219,281 shares of the biotechnology company’s stock worth $470,154,000 after buying an additional 1,370,698 shares in the last quarter. Emerald Acquisition Ltd. purchased a new stake in shares of United Therapeutics Corp. during the second quarter worth $47,352,000. Norges Bank bought a new stake in United Therapeutics Corp. during the fourth quarter worth approximately $65,955,000. Thompson Siegel & Walmsley LLC raised its stake in United Therapeutics Corp. by 140.3% in the second quarter. Thompson Siegel & Walmsley LLC now owns 567,786 shares of the biotechnology company’s stock worth $60,140,000 after buying an additional 331,476 shares during the period. Finally, AQR Capital Management LLC raised its stake in United Therapeutics Corp. by 21.2% in the second quarter. AQR Capital Management LLC now owns 1,584,113 shares of the biotechnology company’s stock worth $167,790,000 after buying an additional 277,266 shares during the period.
United Therapeutics Corp. Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.